



Lund January 27, 2015

## **EXINI's imaging biomarker BSI to be presented at important congress on prostate cancer**

Two clinical studies on EXINI's imaging biomarker BSI (Bone Scan Index) have been approved for the 2015 American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium in Orlando, Florida February 26 - 28. The congress ranks as one of the most important ones and attracts large numbers of internationally acclaimed and influential physicians within the field. The two admitted presentations serves as yet another demonstration of BSI's strength and opens up for deeper discussions between EXINI and decision makers.

*"The medical demand for new biomarkers within treatment of metastatic prostate cancer is acute, especially the need for biomarkers monitoring patients set on new treatments. The two studies, due for the up-coming ASCO-GU congress, proves BSI to be a well functioning response-marker with drugs in use today. This enables us to intensify discussions with key-clinics on introducing BSI for use in daily clinical work flow",* comments Magnus Aurell, CEO, EXINI Diagnostics

### **Details on the two BSI-presentations:**

*Bone scan index as a biomarker to predict outcome in real-life mCRPC patients on abiraterone acetate: A multicenter study.* **Presenting author:** Mariana Reza, Department of Clinical Sciences Malmö, Clinical Physiology, Lund University, Sweden

*Quantitative imaging by automated bone scan index (BSI) as a response biomarker in standard clinical care of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide.* **Presenting author:** Aseem Anand, Department of Clinical Sciences Malmö, Urological Cancer, Lund University, Sweden

Additional information will be published on [www.gucasym.org](http://www.gucasym.org), one week before congress opening.

### **More on Bone Scan Index (BSI)**

BSI is an imaging biomarker providing fast, accurate and quantifiable information to be used for diagnosis and stratification and the monitoring of treatment response. It also provides increased accuracy in prognoses involving patients suffering from skeletal metastases originating from prostate- or breast cancer.

Moreover, BSI has demonstrated its importance in the process of developing new drugs, thus proving itself just as important for clinical use as for the pharmaceutical industry. EXINI bone<sup>BSI</sup> is the only software capable of extracting BSI-values for both these purposes.

[www.bonescanindex.org](http://www.bonescanindex.org)

[www.exini.com/software/exini-bone-bsi/](http://www.exini.com/software/exini-bone-bsi/)

### **For more information, please contact:**

Magnus Aurell, CEO

Phone: +46 46-286 54 25

E-mail: [magnus.aurell@exini.com](mailto:magnus.aurell@exini.com)

### **About EXINI Diagnostics AB (publ)**

EXINI Diagnostics AB (publ) offers advanced solutions for medical decision support to hospitals worldwide. The system is based on advanced image analysis by artificial intelligence and can make its own interpretation of medical images and provide diagnostic suggestions. In this way the system is used as a decision support for the diagnosing doctor. EXINI is working with products for the diagnosis of some of the most frequent endemic diseases such as coronary heart disease, cancer, dementia and Parkinson's disease. EXINI is listed on the stock market NASDAQ First North and has about 600 shareholders. Consensus acts as Certified Adviser.